论文部分内容阅读
2010年7月28日,美国食品药物监督管理局(FDA)批准新分子实体药物阿卡他定(Alcaftadine)滴眼液上市,商品名Lastacaft,用于预防过敏性结膜炎引起的瘙痒。
July 28, 2010, the United States Food and Drug Administration (FDA) approved the new molecular entity drug Alcaftadine (Alcaftadine) eye drops listed under the trade name Lastacaft, for the prevention of allergic conjunctivitis caused itching.